Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Add as a preferred source on Google
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS:CELG), if they purchased the Company’s shares between September 12, 2016 and February 27, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Celgene investors should visit us at https://www.claimsfiler.com/cases/view-celgene-corporation-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Celgene and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On October 19, 2017, the Company disclosed that it was discontinuing trials of its long-touted drug GED-0301 and recording a $1.6 billion impairment charge due to the drug’s failure. Then, on February 27, 2018, the Company revealed that the U.S. Food and Drug Administration had issued a refusal-to-file letter rejecting the New Drug Application (“NDA”) for Ozanimod, another of its leading drug candidates, because “the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.”
On this news, the price of Celgene’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
